AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 92 min read$ORGO

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Organogenesis Holdings Inc. (Nasdaq: ORGO) said it will release second-quarter fiscal 2026 financial results after market close on Aug. 6, 2026. The company will hold a conference call at 5:00 p.m. ET the same day to discuss results and provide a corporate update with Q&A. The webcast will be available on its investor site.

Original reporting
manilatimes.net
Published Jul 9, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 — source image
Source · manilatimes.net
Decision brief

The 30-second read

$ORGONeutralMed
01

Why it matters

The primary trading relevance is the fixed earnings timeline, which can affect options pricing, hedging, and pre-earnings positioning.

02

Market read

A scheduled earnings release after the close on Aug. 6 provides a concrete near-term catalyst, but the article includes no new financial or guidance content.

03

What to watch

The corporate update Q&A could still introduce new information, but this article does not preview any topics beyond the scheduled call.

Relevance 5/10Novelty 5/10Timing: Earnings event scheduled after the close on Aug. 6, 2026.

Background

Organogenesis is a regenerative medicine company focused on advanced wound care and surgical and sports medicine products.

Company-level read

Ticker impact

$ORGONeutralMedium confidence
Context

Organogenesis (ORGO) announced its FY2026 Q2 results will be reported after the close on Aug. 6, with a 5:00 p.m. ET call.

Expected impact

Likely modest pre-earnings positioning and volatility into Aug. 6; direction depends on the Q2 print and any corporate update delivered on the call.

Evidence & confidence

The article contains a concrete, time-specific event (earnings release and conference call) but no financial figures, guidance, or new operational developments.

Market effects

Sector

Regenerative medicine and advanced wound care names may see sector-wide attention around the earnings calendar, but no sector datapoint is provided here.

Regional

No specific regional market linkage is disclosed.

Global

No global macro or cross-border catalyst is mentioned.

Counterpoint

What could challenge this read

Because the release date is already a known type of catalyst, traders may treat it as routine and focus only on the actual Q2 numbers and guidance.

Key entities

  • company
    Organogenesis Holdings Inc.

    Nasdaq-listed regenerative medicine company announcing its FY2026 Q2 results date and conference call details.

  • ticker
    ORGO

    Organogenesis Holdings Inc. common stock ticker on Nasdaq.

Read at source← All news

Related articles

AUG 15
$ORGOMed

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.

yahoo.com10 min
AUG 6
$ORGOMed

Organogenesis Holdings Inc. (ORGO): Results of Operations and Financial Condition

Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 orgo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovat

SEC EDGAR 8-K6 min
JUL 7
$ORGOMedAI 8/10

Organogenesis Secures FDA Review For ReNu In Knee Osteoarthritis

Organogenesis Holdings (ORGO) said the FDA accepted its BLA for ReNu, a cryopreserved amniotic suspension allograft for pain in symptomatic knee osteoarthritis. The company cited 3 randomized trials with 1,300+ patients and prior RMAT designation (2021). FDA set a PDUFA action date of April 24, 2027; “Amnuvx” is conditionally accepted as the proprietary name.

rttnews.com3 min
JUL 6
$ORGOMed

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

Organogenesis Holdings (Nasdaq: ORGO) said the FDA accepted for review its Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis pain. The FDA set a PDUFA target action date of April 24, 2027. The company noted ReNu has RMAT designation and was studied in three RCTs (>1,300 patients).

manilatimes.net3 min
AUG 15
$SLNHMed

Soluna Q2 Earnings Call Highlights

Soluna (NASDAQ: SLNH) reported Q2 net loss of $22.6 million, versus a $7.8 million loss in Q2 2025, driven by non-cash stock compensation, higher interest expense, and a loss on debt extinguishment. Adjusted EBITDA loss was $1.6 million. Revenue rose to $15.1 million. Soluna raised $159.4 million in the quarter and expects operating capacity to increase from 192 MW to 206 MW by summer end.

yahoo.com6 min
AUG 15
$ROCMed

Rank One Computing Q2 Earnings Call Highlights

Rank One Computing (NASDAQ:ROC) reported Q2 product revenue of $2.1M, down 26% YoY, mainly due to ROC Watch revenue falling 87% to $2.1M. Ex-ROC Watch, ROC SDK rose 84% to ~$1.6M, ROC ABIS rose 723% to ~$0.2M, and ROC Enroll rose 125% to ~$0.1M. Gross profit $4.6M, gross margin 90%. Net loss $0.8M. It agreed to acquire ZTC, expected to close by end of Q3.

yahoo.com6 min